Patents by Inventor Sing-Yuen Sit

Sing-Yuen Sit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12275721
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 15, 2025
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jie Chen, Carolyn Diane Dzierba, Junqing Guo, Amy C. Hart, William J. Pitts, Sing-Yuen Sit
  • Publication number: 20250074909
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 28, 2024
    Publication date: March 6, 2025
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Patent number: 12172975
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: December 24, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Junqing Guo, Jie Chen, Carolyn Diane Dzierba, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Sing-Yuen Sit
  • Patent number: 12157733
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: December 3, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Patent number: 11618753
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: April 4, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • Publication number: 20220380335
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: September 12, 2019
    Publication date: December 1, 2022
    Inventors: Junqing Guo, Jie Chen, Carolyn Diane Dzierba, Amy C. Hart, Guanglin Luo, John E. Macor, Willian J. Pitts, Sing-Yuen Sit
  • Publication number: 20220380355
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 2, 2020
    Publication date: December 1, 2022
    Inventors: Jie Chen, Carolyn Diane Dzierba, Junqing Goo, Amy C. Hart, William J. Pitts, Sing-Yuen Sit
  • Patent number: 11464790
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: October 11, 2022
    Assignee: ViiV Healthcare UK (No.4) Limited
    Inventors: Sing-Yuen Sit, Yan Chen, Jacob Swidorski, Alicia Regueiro-Ren
  • Publication number: 20220315580
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: December 9, 2020
    Publication date: October 6, 2022
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Publication number: 20210323997
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: June 9, 2021
    Publication date: October 21, 2021
    Inventors: Jie CHEN, Yan Chen, Ira B. Dicker, Richard A. Hartz, Nicholas A. Meanwell, Beata Nowicka-Sans, Alicia Regueiro-Ren, Sing-Yuen Sit, Ny Sin, Jacob Swidorski, Brian Lee Venables
  • Patent number: 11084845
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: August 10, 2021
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Jie Chen, Yan Chen, Ira B. Dicker, Richard A. Hartz, Nicholas A. Meanwell, Beata Nowicka-Sans, Alicia Regueiro-Ren, Sing-Yuen Sit, Ny Sin, Jacob Swidorski, Brian Lee Venables
  • Patent number: 10913738
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Publication number: 20200360404
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 19, 2020
    Inventors: Sing-Yuen Sit, Yan Chen, Jie Chen, Jacob Swidorski, Brian Lee Venables, Ny Sin, Nicholas A. Meanwell, Alicia Regueiro-Ren, Richard A. Hartz, Li Xu, Zheng Liu
  • Publication number: 20200347071
    Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
    Type: Application
    Filed: January 24, 2019
    Publication date: November 5, 2020
    Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
  • Patent number: 10780102
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: September 22, 2020
    Assignee: VIIV HEALTHCARE UK (NO. 4) LIMITED
    Inventors: Sing-Yuen Sit, Yan Chen, Jie Chen, Jacob Swidorski, Brian Lee Venables, Ny Sin, Nicholas A. Meanwell, Alicia Regueiro-Ren, Richard A. Hartz, Li Xu, Zheng Liu
  • Publication number: 20190389859
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: February 12, 2018
    Publication date: December 26, 2019
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Patent number: 10493070
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: December 3, 2019
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Jie Chen, Nicholas A. Meanwell, Alicia Regueiro-Ren, Sing-Yuen Sit, Jacob Swidorski, Yan Chen
  • Publication number: 20190359647
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: August 7, 2019
    Publication date: November 28, 2019
    Inventors: Jie CHEN, Yan Chen, Ira B. Dicker, Richard A. Hartz, Nicholas A. Meanwell, Beata Nowicka-Sans, Alicia Regueiro-Ren, Sing-Yuen Sit, Ny Sin, Jacob Swidorski, Brian Lee Venables
  • Publication number: 20190307776
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, aza-substituted triterpenoid compounds that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 10, 2019
    Applicant: ViiV HealthCare UK (No. 5) Limited
    Inventors: Jie CHEN, Yan CHEN, Alicia REGUEIRO-REN, Sing-Yuen SIT, Jacob SWIDORSKI
  • Patent number: 10421774
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 24, 2019
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Jie Chen, Yan Chen, Ira B. Dicker, Richard A. Hartz, Nicholas A. Meanwell, Beata Nowicka-Sans, Alicia Regueiro-Ren, Sing-Yuen Sit, Ny Sin, Jacob Swidorski, Brian Lee Venables